Skip to content

Study · Randomized controlled trial · 2021

3 results

Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis.

Tuttle KR, Rayner B, Lakshmanan MC, Kwan AYM, Konig M, Shurzinske L, Botros FT

Kidney3608 Dec 2020Cited by 36 (Europe PMC)

PMID35373017 (opens in a new tab)PMCIDPMC8740994 (opens in a new tab)DOI10.34067/kid.0005852020 (opens in a new tab)PepBankPUB-35373017
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and CKD, dulaglutide reduced the risk of major eGFR decline or ESKD versus insulin glargine.

    In plain wordsIn patients with diabetes and kidney disease, dulaglutide reduced major kidney decline or kidney failure compared with insulin glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseeGFR decline or ESKD
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg weekly · 1 yearAs given in this study (human).

    Measurements

    Event risk
    5%
    dulaglutide
    Event risk
    11%
    insulin glargine
    Hazard ratio
    0.45 ratio
    versus insulin glargine

    Source sentences

    Summary
    Patients treated with 1.5 mg DU weekly versus IG daily for 1 year had a lower risk of ≥40% eGFR decline or ESKD events in the overall study population (5% versus 11%; hazard ratio, 0.45; 95% CI, 0.20 to 0.97; P=0.04).
    1 context sentence
    Summary · context
    Participants with T2DM and CKD categories 3-4 were randomized (1:1:1) to 0.75 or 1.5 mg DU weekly or IG daily as basal therapy, with titrated insulin lispro, for 1 year.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, CKD and macroalbuminuria, dulaglutide reduced composite kidney outcome risk versus insulin glargine.

    In plain wordsIn patients with diabetes, kidney disease and high urine albumin, dulaglutide reduced kidney event risk compared with insulin glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseComposite kidney outcome in macroalbuminuria
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg weekly · 1 yearAs given in this study (human).

    Measurements

    Event risk
    7%
    dulaglutide
    Event risk
    22%
    insulin glargine
    Hazard ratio
    0.25 ratio
    versus insulin glargine

    Source sentences

    Summary
    Most events occurred in the subset of patients with macroalbuminuria, where risk of the composite outcome was substantially lower for 1.5 mg DU versus IG (7% versus 22%; hazard ratio, 0.25; 95% CI, 0.10 to 0.68; P=0.006).
    1 context sentence
    Summary · context
    Participants with T2DM and CKD categories 3-4 were randomized (1:1:1) to 0.75 or 1.5 mg DU weekly or IG daily as basal therapy, with titrated insulin lispro, for 1 year.

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 03HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome

    In AWARD-7 patients with diabetes and CKD, no deaths due to kidney disease occurred.

    In plain wordsNo patients died from kidney disease in the AWARD-7 analysis of dulaglutide and insulin glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableKidney disease deaths
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Mortality · Kidney and urinary

    Source sentences

    Summary
    No deaths due to kidney disease occurred.
    1 context sentence
    Summary · context
    Participants with T2DM and CKD categories 3-4 were randomized (1:1:1) to 0.75 or 1.5 mg DU weekly or IG daily as basal therapy, with titrated insulin lispro, for 1 year.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.